|
| 36763044 | Varied Patterns of Decay of Intact Human Immunodeficiency Virus Type 1 Proviruses Over 2 Decades of Antiretroviral Therapy. | J Infect Dis | 2023 |
| 37650755 | A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable. | AIDS | 2023 |
| 37439051 | U.S. patient preferences for long-acting HIV treatment: a discrete choice experiment. | J Int AIDS Soc | 2023 |
| 36604746 | Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance. | AIDS Res Ther | 2023 |
| 35081558 | Ethnic/Racial Disparities in Longitudinal Neurocognitive Decline in People With HIV. | J Acquir Immune Defic Syndr | 2022 |
| 35773234 | Neuropathic pain correlates with worsening cognition in people with human immunodeficiency virus. | Brain | 2022 |
| 35381084 | Reply to Bottanelli et al. | J Infect Dis | 2022 |
| 35535576 | Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy. | J Infect Dis | 2022 |
| 36039892 | Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. | J Int AIDS Soc | 2022 |
| 35216610 | The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies in the United States. | AIDS Res Ther | 2022 |
| 32823274 | Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. | J Infect Dis | 2021 |
| 33685272 | "Lighten This Burden of Ours": Acceptability and Preferences Regarding Injectable Antiretroviral Treatment Among Adults and Youth Living With HIV in Coastal Kenya. | J Int Assoc Provid AIDS Care | 2021 |
| 33487029 | Poor quality of life and incomplete self-reported adherence predict second-line ART virological failure in resource-limited settings. | AIDS Care | 2021 |
| 33565583 | Paresthesia Predicts Increased Risk of Distal Neuropathic Pain in Older People with HIV-Associated Sensory Polyneuropathy. | Pain Med | 2021 |
| 33831905 | Antiretroviral hair levels, self-reported adherence, and virologic failure in second-line regimen patients in resource-limited settings. | AIDS | 2021 |
| 34788110 | Participants Switching to Second-Line Antiretroviral Therapy with Susceptible Virus Display Inferior Adherence and Worse Outcomes: An Observational Analysis. | AIDS Patient Care STDS | 2021 |
| 34127579 | Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria. | AIDS | 2021 |
| 32603416 | Association of Male Sex and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-Term Antiretroviral Therapy. | J Infect Dis | 2021 |
| 31563942 | Screening and Enrollment by Sex in Human Immunodeficiency Virus Clinical Trials in the United States. | Clin Infect Dis | 2020 |
| 34589877 | Higher levels of plasma inflammation biomarkers are associated with depressed mood and quality of life in aging, virally suppressed men, but not women, with HIV. | Brain Behav Immun Health | 2020 |
| 31724034 | Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings. | Clin Infect Dis | 2020 |
| 32049773 | Brief Report: Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral Therapy. | J Acquir Immune Defic Syndr | 2020 |
| 31655915 | A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antiretroviral Therapy Among Persons Living with HIV in the U.S. | AIDS Behav | 2020 |
| 32006525 | Integration of Computational and Experimental Approaches to Elucidate Mechanisms of First-Pass Lymphatic Drug Sequestration and Long-Acting Pharmacokinetics of the Injectable Triple-HIV Drug Combination TLC-ART 101. | J Pharm Sci | 2020 |
| 32619341 | Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV. | Ann Clin Transl Neurol | 2020 |
| 32841299 | Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment. | PLoS Pathog | 2020 |
| 31576785 | Use of Neuroimaging to Inform Optimal Neurocognitive Criteria for Detecting HIV-Associated Brain Abnormalities. | J Int Neuropsychol Soc | 2020 |
| 30642925 | Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202. | Antimicrob Agents Chemother | 2019 |
| 30209774 | Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection. | Mol Neurobiol | 2019 |
| 31528850 | Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial. | Lancet Digit Health | 2019 |
| 31371262 | Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. | Lancet HIV | 2019 |
| 31335587 | Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART. | J Acquir Immune Defic Syndr | 2019 |
| 31305262 | Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance. | J Clin Invest | 2019 |
| 30990052 | Acceptability of Cell and Gene Therapy for Curing HIV Infection Among People Living with HIV in the Northwestern United States: A Qualitative Study. | AIDS Res Hum Retroviruses | 2019 |
| 30870195 | Effects of comorbidity burden and age on brain integrity in HIV. | AIDS | 2019 |
| 30890191 | Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates. | J Int Neuropsychol Soc | 2019 |
| 30702516 | Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects. | AIDS | 2019 |
| 30973942 | Increased mucosal neutrophil survival is associated with altered microbiota in HIV infection. | PLoS Pathog | 2019 |
| 30844308 | Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV. | AIDS Patient Care STDS | 2019 |
| 30291567 | White matter damage, neuroinflammation, and neuronal integrity in HAND. | J Neurovirol | 2019 |
| 28874213 | Differences in Neurocognitive Impairment Among HIV-Infected Latinos in the United States. | J Int Neuropsychol Soc | 2018 |
| 30102655 | Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates. | AIDS | 2018 |
| 30085241 | The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. | J Infect Dis | 2018 |
| 29756456 | No Time to Delay! Fiebig Stages and Referral in Acute HIV infection: Seattle Primary Infection Program Experience. | AIDS Res Hum Retroviruses | 2018 |
| 29584723 | Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort. | PLoS Med | 2018 |
| 29471387 | Heavy Cannabis Use Associated With Reduction in Activated and Inflammatory Immune Cell Frequencies in Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Individuals. | Clin Infect Dis | 2018 |
| 29548975 | Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection. | J Pharm Sci | 2018 |
| 29432823 | Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation. | J Control Release | 2018 |
| 29334547 | Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women. | AIDS | 2018 |
| 29272346 | Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis. | Clin Infect Dis | 2018 |